Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (114)	7/6/2000 12:55:09 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 164

Here was the Nov. '99 Press report - before the more rigid standards were used. SYNSORB Biotech Inc. Announces Company Receives Final Interim Analysis Report for SYNSORB Cd(R) Phase II Clinical Trial NOVEMBER 1, 1999 CALGARY, ALBERTA-- Company also reports on progress of SYNSORB Cd(R) clinical development plan SYNSORB Biotech Inc. ("SYNSORB") (TSE: SYB, Nasdaq: SYBB) after receiving the final report on the interim analysis of the SYNSORB Cd(R) Phase II clinical trial, reports on the Company's recent progress in the development of SYNSORB Cd(R) for the treatment of recurrent Clostridium difficile Associated Diarrhea (CDAD). The primary objective and expectation of the Phase II trial was to determine whether SYNSORB Cd(R) could reduce the recurrence rate in CDAD patients by 50%. In fact, the final report on the interim analysis of the first 103 patients has confirmed that the group receiving a 16g/day dose of SYNSORB Cd(R) experienced a very significant 80% reduction in the rate of recurrence compared to the group who received the placebo. Jim